• Pharming flagged positive topline Phase II data for leniolisib in certain primary immunodeficiencies with immune dysregulation.
• Results have not yet been presented; the late-breaking abstract is slated for ESID 2026 on Oct. 14-17.
• The study showed the drug was generally well tolerated, with broad clinical improvement in immune dysregulation, including reduced lymphoproliferation.
• A separate Phase II trial in common variable immunodeficiency is expected to deliver topline results in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220100PRIMZONEFULLFEED1001273900) on September 22, 2026, and is solely responsible for the information contained therein.